Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)GlobeNewsWire • 06/12/26
Pharma and Biotech M&A Boom Accelerates as Companies Expand PipelinesZacks Investment Research • 06/11/26
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease StudyBenzinga • 06/11/26
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpointGlobeNewsWire • 06/11/26
Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue MedicinesBusiness Wire • 06/10/26
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026GlobeNewsWire • 06/08/26
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 yearsGlobeNewsWire • 06/04/26
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patientsGlobeNewsWire • 06/03/26
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseasesGlobeNewsWire • 06/01/26
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancerGlobeNewsWire • 05/31/26
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strengthGlobeNewsWire • 05/26/26
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHAGlobeNewsWire • 05/21/26
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancerGlobeNewsWire • 05/17/26
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilitiesGlobeNewsWire • 05/07/26
UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policiesCNBC • 04/29/26